Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 162Myelodysplastic Syndromes 46Leukemia, Myelomonocytic, Chronic 26Leukemia 16Myeloproliferative Disorders 11Recurrence 9Hematologic Neoplasms 8Leukemia, Biphenotypic, Acute 7Primary Myelofibrosis 6Neoplasms 6Lymphoma, T-Cell, Peripheral 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Anemia, Refractory, with Excess of Blasts 5Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Leukemia, Monocytic, Acute 4Hematologic Diseases 4GATA2 Deficiency 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Sarcoma 2

Interventions

cc-486 1Raltegravir Potassium 1Blood Specimen Collection 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatic Insufficiency × Azacitidine × 1 year × Clear all
NCT05209295 2026-01-12

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Bristol-Myers Squibb

Phase 1 Terminated
2 enrolled

Neoplasms, Hepatic Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡